Visceral and subcutaneous fat in patients treated with olanzapine: a case series.
OBJECTIVE
We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome.


METHODS
Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients.


RESULTS
We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body.


CONCLUSIONS
On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome.
Gilles
Maria
M
Department of Psychiatry and Psychotherapy, and †Neuroradiology, Central Institute of Mental Health, Mannheim, Germany.
Hentschel
Frank
F
Paslakis
Georgios
G
Glahn
Valerie
V
Lederbogen
Florian
F
Deuschle
Michael
M
D050154:Adiposity; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D050152:Intra-Abdominal Fat / Q000000981:diagnostic imaging / Q000187:drug effects*; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy; D050507:Subcutaneous Fat, Abdominal / Q000000981:diagnostic imaging / Q000187:drug effects*; D014057:Tomography, X-Ray Computed; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine